Cargando…
TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell
BACKGROUND: Oxaliplatin is the first-choice chemotherapy method for patients with advanced colon cancer. However, its resistance leads to treatment failure for many patients. In our experiments, we aim to elucidate the associations among TRIM29 protein, mutant P53, and the resistance of colon cancer...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007381/ https://www.ncbi.nlm.nih.gov/pubmed/33824865 http://dx.doi.org/10.1155/2021/8870907 |